Long-term side-effects following therapy with cyproterone acetate;Langzeitnebenwirkungen nach cyproteronacetathaltiger therapie in der gynakologie

Zentralblatt fur Gynakologie

Volumn 122, Issue 5, 2000, Pages 268-273

  Regidor, P A ^b   Speer, K ^b   Regidor, M ^b   Schindler, E M ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b NONE

Author keywords

Cyproterone acetate (CPA); Liver cell carcinoma; Long term follow up; Side effects

Indexed keywords

CYPROTERONE ACETATE; DIANE;

AFFECTIVE NEUROSIS; ARTICLE; DNA ADDUCT; DRUG INDUCED DISEASE; DRUG SCREENING; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; LEG EDEMA; LIVER CELL CARCINOMA; LONG TERM CARE; MASTALGIA; MIGRAINE; SKIN MANIFESTATION; WEIGHT GAIN;

ADULT; ANDROGEN ANTAGONISTS; CARCINOMA, HEPATOCELLULAR; CYPROTERONE ACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HIRSUTISM; HUMANS; LIVER NEOPLASMS; RISK FACTORS;

EID: 0034078372     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bader H. Lehrbuch der Pharmakologie und Toxikologie. 2. Aufl. edition medizin, 1985
2. Barth JH, Cherry CA, Woynarowska A. Cyproterone acetate for severe hirsutism: results of a double-bind dose-ranging study. Clinical Endocrinology 1991; 35: 5-10
3. Erdmann D, Schindler E-M, Schindler AE. Die ovarielle Suppression unter Diane 35/50®. Geburtsh u Frauenheilk 1994; 54: 627-633
4. Estler C-J. Pharmakologie und Toxikologie. 4. Aufl. Schattauer, 1994
5. Formann D, Vincent TJ, Doll R. Cancer of the liver and the use of oral contraceptives. Br Med J (Clin Res Ed) 1986; 292 (6532): 1357-1361
6. Forth W, Henschler D, Rummel W, Starke K. Pharmakologie und Toxikologie. 6. Aufl. B I Wissenschaftsverlag, 1992
7. Heinemann LAJ. Will-Shahab L, van Kesteren P, Gooren LJG. Safty of Cyproterone Acetate: Report of Active Surveillance. Pharmacoepidemiology and Drug Safety 1997; 6: 169-178
8. Keck C, Wilhelm C, Breckwoldt M. Einfluß oraler Kontrazeptiva auf die Entwicklung von Lebertumoren. Fertilität 1996; 12: 207-211
9. Knörr, Knörr-Gärtner, Beller F.K, Lauritzen Ch. Geburtshilfe und Gynäkologie. 3. Aufl. Springer, 1989
10. Krebs O, Schäfer B, Wolff Th, Oesterle D, Demi E, Sund M, Favor J. The DNA damaging drug cyproterone acetate causes gene mutations and induces glutathine-S-transferase P in the liver of female Big Blue™ transgenic F344 rats. Carcinogenesis 1998; 19: 241-245
11. Kuschinsky G, Lüllmann H. Kurzes Lehrbuch der Pharmakologie und Toxikologie. 12. Aufl. Thieme, 1989
12. Mutschler E. Arzneimittelwirkungen, Lehrbuch der Pharmakologie und Toxikologie. 7. Aufl. Wissenschaftliche Verlags-gesellschaft mbH, Stuttgart 1996
13. Neumann I, D, Andrae U, Greim H, Schwarz LR. Cyproterone acetate induces DNA damages in cultured rat hepatocytes and preferentially stimulates DNA synthesis in γ-glutamyltranspeptidase-positive cells. Carcinogenesis 1992; 13: 373-378
14. Ohri SK, Gaer JAR, Keane PF. Hepatocellular carcinoma and treatment with cyproterone acetate. British Journal of Urology 1991; 67: 213
15. Prentice RL. Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Preventive Medicine 1991; 20: 38-46
16. Rabe T, Feldmann K, Grunwald K, Runnebaum B. Liver tumors in woman on oral contraceptives. Lancet, letter to the editor 1994; 344: 1568
17. Rabe T, Feldmann K, Grunwald K, Runnebaum B. Lebertumoren bei Frauen unter Anwendung von oralen hormonalen Kontrazeptiva - Kurzmitteilung. Zentralbl Gynakol 1995; 117: 153-156
18. Ricca Rosellini S, Miglio F. Epidemiology of hepatocellular carcinoma. Minerva Gastroenterol Dietol 1991; 37: 73-84
19. Rooks JB, Ory HW, Ishak KG, Strauss LT, Grunspann JR, Hill AP, Tylor CW Jr. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979; 242: 644-648
20. Rüdiger T, Beckmann J, Queißer W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol. Lancet, letter to the editor 1995; 345
21. Topinka J, Andrae U, Schwarz LR, Wolff T. Cyproterone acetate generates DNA adducts in rat liver and in primary rat hepatocyte cultures. Carcinogenesis 1993; 14: 423-427
22. Watanabe S, Yamasaki S, Tanae A, Hibi I. Three cases of hepatocellular carcinoma among cyproterone users. Lancet, letter to the editor 1994; 344: 1567-1568